Evidence map›Paper›PMID 34584911›Full record

ArticleRegenerative therapy2021

Development of alternative gene transfer techniques for

Masashi Noda, Kohei Tatsumi, Hideto Matsui, Yasunori Matsunari, Takeshi Sato, Yasushi Fukuoka, Akitsu Hotta, Teruo Okano, Kimihiko Kichikawa, Mitsuhiko Sugimoto and 2 more

Open access · goldAbstract read
In one paragraph

Article in Regenerative therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Masashi NodaDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Kohei TatsumiAdvanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Japan.
Hideto MatsuiDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Yasunori MatsunariDepartment of Anesthesiology, Nara Medical University, Kashihara, Japan.
Takeshi SatoDepartment of Diagnostic Radiology and IVR, Nara Medical University, Kashihara, Japan.
Yasushi FukuokaDepartment of Diagnostic Radiology and IVR, Nara Medical University, Kashihara, Japan.
Akitsu HottaDepartment of Reprogramming Science, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Teruo OkanoInstitute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.
Kimihiko KichikawaDepartment of Diagnostic Radiology and IVR, Nara Medical University, Kashihara, Japan.
Mitsuhiko SugimotoDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Midori ShimaNara Medical University, Kashihara, Japan.
Kenji NishioDepartment of General Medicine, Nara Medical University, Kashihara, Japan.
Nara Medical University · JPKyoto University · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGene therapy have recently attracted much attention as a curative therapeutic option for inherited single gene disorders such as hemophilia. Hemophilia is a hereditary bleeding disorder caused by the deficiency of clotting activity of factor VIII (FVIII) or factor IX (FIX), and gene therapy for hemophilia using viral vector have been vigorously investigated worldwide. Toward further advancement of gene therapy for hemophilia, we have previously developed and validated the efficacy of novel two types of gene transfer technologies using a mouse model of hemophilia A. Here we investigated the efficacy and safety of the technologies in canine model. Especially, validations of technical procedures of the gene transfers for dogs were focused.

methodsGreen fluorescence protein (GFP) gene were transduced into normal beagle dogs by

resultsNo major adverse events were observed during the gene transfers in both gene transfer systems. As for

conclusionsTwo types of gene transfer techniques were successfully applied to a canine model, and the transduced gene expressions persisted for a long term. Toward clinical application for hemophilia patients, practical assessments of therapeutic efficacy of these techniques will need to be performed using a dog model of hemophilia and FVIII (or FIX) gene.

Indexed as

BOEC, blood outgrowth endothelial cellCell sheetDogFIX, factor IXFVIII, factor VIIIGene therapyGFP, green fluorescent proteinHemophiliaHydrodynamic injection

Identifiers

PMID34584911
PMCPMC8441024
OpenAlexW3200814405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.